Dario Bencivelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dario Bencivelli has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Alessandro Borghi
Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
4 shared publications - Monica Corazza
Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
4 shared publications Antonella Rotola
Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy
2 shared publicationsElisabetta Danese
Section of Dermatology and Infectious Diseases, Department of Medical Sciences, University of Ferrara, Ferrara, Italy
2 shared publicationsGiovanna Schiuma
Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy
2 shared publicationsSabrina Rizzo
Department of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy
2 shared publications
Latest Publications
- Open Access
- 15 February 2022
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 23 (1) , 79-85
Inhibitory KIR2DL2 receptor and HHV-8 in classic or endemic Kaposi sarcoma
KIR2DL2, an inhibitory Killer cell Immunoglobulin-like Receptor (KIR), has been shown to predispose to the development of several herpesvirus-associated diseases by inhibiting the efficiency of Natural Killer (NK) cells against virus-infected cells. The aim of this observational study was to assess the prevalence of KIR2DL2 and Human Herpes Virus 8 (HHV8) in patients affected with classical and endemic Kaposi sarcoma (KS), as well as in controls. Blood samples collected from 17 Caucasian, HIV-negative, immunocompetent patients affected with classical KS (c-KS), 12 African, HIV-negative patients with endemic KS (e-KS), 83 healthy subjects and 26 psoriatic patients were processed for genotypization by PCR for two KIR alleles, such as KIR2DL2 and KIR2DL3 and analyzed for HHV-8 presence. The totality of both c-KS and e-KS patients presented HHV-8 infection, whereas HHV8 was found in 26.9% of psoriatic subjects and 19.3% of healthy subjects. KIR2DL2 was found in the 76.5% of c-KS subjects, while the receptor was found in 41.7% of the e-KS group, 34.6% of psoriatic patients and 43.4% of healthy controls (p < 0.0001). A significantly higher prevalence of KIR2DL2 in c-KS patients than in all the other subjects was also confirmed comparing age-matched groups. Based on these results, the inhibitory KIR2DL2 genotype appears to be a possible cofactor which increases the risk of developing c-KS in HHV8-positive, immunocompetent subjects, while it seems less relevant in e-KS pathogenesis.
- 15 February 2022
- Published by Springer Nature in Clinical and Experimental Medicine
- Vol. 23 (1) , 79-85
Open AccessInhibitory KIR2DL2 receptor and HHV-8 in classic or endemic Kaposi sarcoma
KIR2DL2, an inhibitory Killer cell Immunoglobulin-like Receptor (KIR), has been shown to predispose to the development of several herpesvirus-associated diseases by inhibiting the efficiency of Natural Killer (NK) cells against virus-infected cells. The aim of this observational study was to assess the prevalence of KIR2DL2 and Human Herpes Virus 8 (HHV8) in patients affected with classical and endemic Kaposi sarcoma (KS), as well as in controls. Blood samples collected from 17 Caucasian, HIV-negative, immunocompetent patients affected with classical KS (c-KS), 12 African, HIV-negative patients with endemic KS (e-KS), 83 healthy subjects and 26 psoriatic patients were processed for genotypization by PCR for two KIR alleles, such as KIR2DL2 and KIR2DL3 and analyzed for HHV-8 presence. The totality of both c-KS and e-KS patients presented HHV-8 infection, whereas HHV8 was found in 26.9% of psoriatic subjects and 19.3% of healthy subjects. KIR2DL2 was found in the 76.5% of c-KS subjects, while the receptor was found in 41.7% of the e-KS group, 34.6% of psoriatic patients and 43.4% of healthy controls (p < 0.0001). A significantly higher prevalence of KIR2DL2 in c-KS patients than in all the other subjects was also confirmed comparing age-matched groups. Based on these results, the inhibitory KIR2DL2 genotype appears to be a possible cofactor which increases the risk of developing c-KS in HHV8-positive, immunocompetent subjects, while it seems less relevant in e-KS pathogenesis.
- Open Access
- 6 January 2022
- Published by Springer Nature in Research Square
Inhibitory KIR2DL2 Receptor and HHV-8 in Classic or Endemic Kaposi Sarcoma
KIR2DL2, an inhibitory Killer cell Immunoglobulin-like Receptor (KIR), has been shown to predispose to the development of several herpesvirus-associated diseases by inhibiting the efficiency of Natural Killer (NK) cells against virus-infected cells. The aim of this observational study was to assess the prevalence of KIR2DL2 and Human Herpes Virus 8 (HHV8) in patients affected with classical and endemic Kaposi sarcoma (KS), as well as in controls. Blood samples collected from 17 Caucasian, HIV-negative, immunocompetent patients affected with classical KS (c-KS), 12 African, HIV-negative patients with endemic KS (e-KS), 83 healthy subjects and 26 psoriatic patients were processed for genotypization by PCR for two KIR alleles, such as KIR2DL2 and KIR2DL3 and analyzed for HHV-8 presence. The totality of both c-KS and e-KS patients presented HHV-8 infection, whereas HHV8 was found in 26.9% of psoriatic subjects and 19.3% of healthy subjects. KIR2DL2 was found in the 76.5% of c-KS subjects, while the receptor was found in 41.7% of the e-KS group, 34.6% of psoriatic patients and 43.4% of healthy controls (p<0.0001). A significantly higher prevalence of KIR2DL2 in c-KS patients than in all the other subjects was also confirmed comparing age-matched groups. Based on these results, the inhibitory KIR2DL2 genotype appears to be a possible cofactor which increases the risk of developing c-KS in HHV8-positive, immunocompetent subjects, while it seems less relevant in e-KS pathogenesis.
- 6 January 2022
- Published by Springer Nature in Research Square
Open AccessInhibitory KIR2DL2 Receptor and HHV-8 in Classic or Endemic Kaposi Sarcoma
KIR2DL2, an inhibitory Killer cell Immunoglobulin-like Receptor (KIR), has been shown to predispose to the development of several herpesvirus-associated diseases by inhibiting the efficiency of Natural Killer (NK) cells against virus-infected cells. The aim of this observational study was to assess the prevalence of KIR2DL2 and Human Herpes Virus 8 (HHV8) in patients affected with classical and endemic Kaposi sarcoma (KS), as well as in controls. Blood samples collected from 17 Caucasian, HIV-negative, immunocompetent patients affected with classical KS (c-KS), 12 African, HIV-negative patients with endemic KS (e-KS), 83 healthy subjects and 26 psoriatic patients were processed for genotypization by PCR for two KIR alleles, such as KIR2DL2 and KIR2DL3 and analyzed for HHV-8 presence. The totality of both c-KS and e-KS patients presented HHV-8 infection, whereas HHV8 was found in 26.9% of psoriatic subjects and 19.3% of healthy subjects. KIR2DL2 was found in the 76.5% of c-KS subjects, while the receptor was found in 41.7% of the e-KS group, 34.6% of psoriatic patients and 43.4% of healthy controls (p<0.0001). A significantly higher prevalence of KIR2DL2 in c-KS patients than in all the other subjects was also confirmed comparing age-matched groups. Based on these results, the inhibitory KIR2DL2 genotype appears to be a possible cofactor which increases the risk of developing c-KS in HHV8-positive, immunocompetent subjects, while it seems less relevant in e-KS pathogenesis.
- 20 February 2021
- Published by Wiley in Contact Dermatitis
- Vol. 85 (2) , 246-249
Occupational allergic contact dermatitis in a basket player due to phenolic resins
- 20 February 2021
- Published by Wiley in Contact Dermatitis
- Vol. 85 (2) , 246-249
Occupational allergic contact dermatitis in a basket player due to phenolic resins
- Open Access
- 4 January 2021
- Published by Wiley in Contact Dermatitis
- Vol. 84 (6) , 466-467
Severe contact urticaria, mimicking allergic contact dermatitis, due to a surgical mask worn during the COVID‐19 pandemic
- 4 January 2021
- Published by Wiley in Contact Dermatitis
- Vol. 84 (6) , 466-467
Open AccessSevere contact urticaria, mimicking allergic contact dermatitis, due to a surgical mask worn during the COVID‐19 pandemic
- 6 March 2020
- Published by Wiley in Contact Dermatitis
- Vol. 83 (2) , 125-126
Allergic contact dermatitis to nickel: Can systemic isotretinoin therapy promote sensitization?
- 6 March 2020
- Published by Wiley in Contact Dermatitis
- Vol. 83 (2) , 125-126
Allergic contact dermatitis to nickel: Can systemic isotretinoin therapy promote sensitization?
- 30 August 2013
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 129 (4) , 276-281
A2Aadenosine receptors and Parkinson's disease severity
Objectives In the last decade, increasing evidence suggests a key role of adenosine in Parkinson's disease (PD) and A2A adenosine receptors (A2AARs) as an important pharmacological target in PD. An overexpression of A2AARs has been found in putamen and in peripheral blood cells of PD patients. The primary aim of this study was to verify whether the alterations in A2AARs in lymphocytes of PD subjects correlate with disease severity. Material and methods A consecutive sample of PD patients was enrolled. A clinical examination and a face‐to‐face interview were carried out. A2AARs were investigated to verify the affinity and receptor density in lymphocyte membranes. The data were compared with those found in healthy controls. Moreover, the correlation between A2AAR density and affinity and clinical variables was evaluated in PD patients. Results In human lymphocyte membranes from PD patients, an increase in A2AAR density and a decrease in A2AAR affinity were found if compared with healthy subjects. A statistically significant correlation between the A2AAR density or affinity and specific clinical parameters as motor and cognitive impairment was detected. Patients with higher A2AAR density and lower affinity were more likely to exhibit motor complications. Conclusions Parkinson's disease patients show an A2AAR upregulation in lymphocyte membranes if compared with healthy subjects. The correlation found between A2AAR density or affinity and clinical parameters highlights the central role of A2AAR modulation in the pharmacological treatment for PD and could suggest the putative role of A2AAR as a candidate biomarker of PD severity.
- 30 August 2013
- Published by Hindawi Limited in Acta Neurologica Scandinavica
- Vol. 129 (4) , 276-281
A2Aadenosine receptors and Parkinson's disease severity
Objectives In the last decade, increasing evidence suggests a key role of adenosine in Parkinson's disease (PD) and A2A adenosine receptors (A2AARs) as an important pharmacological target in PD. An overexpression of A2AARs has been found in putamen and in peripheral blood cells of PD patients. The primary aim of this study was to verify whether the alterations in A2AARs in lymphocytes of PD subjects correlate with disease severity. Material and methods A consecutive sample of PD patients was enrolled. A clinical examination and a face‐to‐face interview were carried out. A2AARs were investigated to verify the affinity and receptor density in lymphocyte membranes. The data were compared with those found in healthy controls. Moreover, the correlation between A2AAR density and affinity and clinical variables was evaluated in PD patients. Results In human lymphocyte membranes from PD patients, an increase in A2AAR density and a decrease in A2AAR affinity were found if compared with healthy subjects. A statistically significant correlation between the A2AAR density or affinity and specific clinical parameters as motor and cognitive impairment was detected. Patients with higher A2AAR density and lower affinity were more likely to exhibit motor complications. Conclusions Parkinson's disease patients show an A2AAR upregulation in lymphocyte membranes if compared with healthy subjects. The correlation found between A2AAR density or affinity and clinical parameters highlights the central role of A2AAR modulation in the pharmacological treatment for PD and could suggest the putative role of A2AAR as a candidate biomarker of PD severity.